BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 24, 2007
 |  BioCentury  |  Strategy

Big antibody deals

Big antibody deals

Partners Year Potential value Description
Genmab (CSE:GEN) GlaxoSmithKline (LSE:GSK; GSK) 2006 $2,059 GSK receives global exclusive rights to co-develop and commercialize GEN's ofatumumab for cancer and autoimmune diseases. The biotech receives a DKK582M ($102M) license fee, a DKK2B ($357M) equity investment and is eligible for up to DKK9B ($1.6B) in milestones plus double-digit royalties.
Ablynx (Euronext:ABLX) Boehringer Ingelheim 2007 $1,805 (A) Partner to use ABLX's Nanobody technology to discover, develop and commercialize up to 10 therapeutic proteins against undisclosed targets to treat cancer, immunological and respiratory diseases. The biotech receives a E15M ($20.4M) equity investment up front and up to E60M ($81.8M)...

Read the full 583 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >